US Broker Ratings

Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Navigating a 16.82% Potential Upside in the Medical Devices Sector

Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a key player in the medical devices industry, has captured investor attention with a market capitalization of $17.41 billion and intriguing growth prospects. As..

Ionis Pharmaceuticals (IONS): Investor Outlook on a Biotech Innovator with 32% Upside Potential

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a pioneering biotech company based in Carlsbad, California, presents an intriguing investment opportunity for those looking to delve into the biotechnology sector. With a substantial..

Option Care Health, Inc. (OPCH) Stock Analysis: A 42% Upside Potential Amidst Strong Buy Ratings

Option Care Health, Inc. (NASDAQ: OPCH), a dominant player in the U.S. healthcare sector, is drawing significant investor attention with its robust service offerings in home and alternate site infusion..

Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 26% Potential Upside in the Healthcare Sector

Investors eyeing opportunities in the healthcare sector might find Teleflex Incorporated (NYSE: TFX) an intriguing prospect, particularly given its potential upside of 26.38%. With a market cap of $4.66 billion,..

Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Unpacking a 41.77% Potential Upside for Investors

Investors eyeing the healthcare sector may want to take a closer look at Axsome Therapeutics, Inc. (NASDAQ: AXSM), a burgeoning player in the biotechnology industry. With a market capitalization of..

Merit Medical Systems, Inc. (MMSI) Stock Analysis: Exploring a Potential 52.90% Upside

Investors keen on the healthcare sector may find Merit Medical Systems, Inc. (NASDAQ: MMSI) an intriguing prospect. With a current market capitalization of $3.96 billion, the company operates within the..

Waters Corporation (WAT) Investor Outlook: Analyzing the 33% Potential Upside Driven by Strong Analyst Ratings

Waters Corporation (NYSE: WAT) stands as a formidable player in the healthcare sector, particularly within the Diagnostics & Research industry. With a market cap of $29.33 billion, Waters Corporation has..

Viatris Inc. (VTRS) Stock Analysis: Navigating a Complex Healthcare Landscape with a 17% Potential Upside

Viatris Inc. (VTRS), a prominent player in the healthcare sector, is forging a path through the complex landscape of drug manufacturing with a focus on both specialty and generic products...

AstraZeneca PLC (AZN) Stock Analysis: Evaluating Growth Potential Amid a 13.53% Upside

AstraZeneca PLC (NASDAQ: AZN), a leading player in the healthcare sector, is drawing investor attention with a market capitalization of $284.63 billion and a strong presence in the biopharmaceutical landscape...

Alcon Inc. (ALC)

⚠️ No article content returned.

..

Vertex Pharmaceuticals (VRTX) Stock Analysis: Healthcare Innovator with 20.62% Potential Upside

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stands as a formidable force in the biotechnology sector, particularly within the healthcare industry. With its headquarters in Boston, Massachusetts, Vertex is renowned for delivering..

AptarGroup, Inc. (ATR) Stock Analysis: Capitalize on a 34.64% Potential Upside in the Growing Healthcare Sector

Investors seeking opportunities in the healthcare sector should closely examine AptarGroup, Inc. (NYSE: ATR), a leader in the design and manufacturing of drug delivery and consumer product dispensing solutions. With..

Revolution Medicines (RVMD) Stock Analysis: A Look at the 39.59% Potential Upside in Precision Oncology

Investors are turning their attention to Revolution Medicines, Inc. (NASDAQ: RVMD), a trailblazer in the healthcare sector, specifically within the biotechnology industry. With a market capitalization of $18.98 billion, this..

BeOne Medicines Ltd. (ONC) Stock Analysis: Biotechnology Innovator with a 49% Upside Potential

BeOne Medicines Ltd. (NASDAQ: ONC), a prominent player in the biotechnology sector, has caught the attention of investors with its substantial growth potential. Based in Basel, Switzerland, this oncology-focused company..

Takeda Pharmaceutical Company L (TAK): Investor Outlook on a 9.71% Potential Upside

Takeda Pharmaceutical Company Limited (NYSE: TAK), a stalwart in the pharmaceutical industry, commands attention with its robust market presence and innovative drug portfolio. With a market capitalization of $56.33 billion,..

Charles River Laboratories (CRL) Stock Analysis: Exploring a 28.56% Potential Upside

Investors eyeing opportunities in the healthcare sector might find Charles River Laboratories International, Inc. (NYSE: CRL) an enticing prospect, especially given its significant potential upside. With an average target price..

Masimo Corporation (MASI) Stock Analysis: Navigating Healthcare Innovation with Strong Revenue Growth

Masimo Corporation (NASDAQ: MASI), a stalwart in the healthcare sector, particularly within the medical devices industry, continues to capture investor attention with its innovative approach to patient monitoring technologies. Headquartered..

BioNTech SE (BNTX) Stock Analysis: Navigating a 48% Potential Upside Amidst Volatile Financials

BioNTech SE (NASDAQ: BNTX), a prominent player in the biotechnology sector, has garnered significant attention from investors worldwide, particularly for its pioneering work in developing immunotherapies and mRNA vaccines. With..

Avantor, Inc. (AVTR) Stock Analysis: Evaluating a Potential 44.57% Upside in the Healthcare Sector

Avantor, Inc. (NYSE: AVTR), a key player in the healthcare sector, specializes in providing mission-critical products and services across a diverse range of industries including biopharma, healthcare, education, and advanced..

Grifols, S.A. (GRFS) Stock Analysis: Exploring a 46% Potential Upside in the Healthcare Sector

Grifols, S.A. (NYSE: GRFS), a major player in the healthcare sector, has caught the attention of investors with its promising potential for significant upside. With a current stock price of..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds